Indeed, FDA-approved drugs (abciximab, integrilin and tirofiban) that block GPIIb-IIIa are of benefit as antithrombotic therapy in acute coronary syndromes [21], and in animal models, antagonism of platelet surface P-selectin [22] and platelet surface GPIb [23] has antithrombotic benefit. This evidence concerns the gene SELP and acute coronary syndrome.